KCT0008726尚未招募Unknown
A randomized phase 3 trial of adding docetaxel to ADT plus ARTA in patients with metastatic hormone-sensitive prostate cancer
Hanyang University Seoul Hospital0 个研究点目标入组 430 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- Male
入选标准
- •1) A person who voluntarily agrees to participate in this study in writing
- •2) 18 years of age or older
- •3) Histologically or cytologically diagnosed prostate cancer (excluding neuroendocrine differentiation or small-cell histological feature)
- •4) De novo patients identified as metastatic disease in CT, MR, or Bone scan at the time of prostate cancer diagnosis
- •5) Patients under administration of ADT (LHRHagonist/antagonist orchiectomy) and ARTA (Abiraterone, Apalutamide, or Enzalutamide) prior to registration; however, the administration period of ADT and ARTA prior to registration shall not exceed 12 weeks.
- •6) ECOG PS 0-2
- •7) Adequate bone marrow function (absolute neutrophil count =1500/mm3 (=1.5×103/µL), platelet =100,000/mm2 (=100x109/L), and hemoglobin =9.0 g/L), appropriate kidney function (hemolytic creatinine <1.5xnormal), appropriate hepatic function (Total xtransferase 3 upper limit), If there are no abnormalities in other liver function tests, including gamma glutamyl transfertase (GGT), and extensive bone metastasis is accompanied, it is judged to be an increase due to bone metastasis, and up to 6.0 x normal upper limit can be registered.)
- •8) Radiotherapy for symptom control purposes for bone metastatic lesions is acceptable
- •9) Subjects who agree to use contraception (maintain abstinence or use male condoms for sexual intercourse) during the treatment period and for 6 months after the last dose
- •10) A person who understands the contents of a clinical trial, is cooperative in conducting the test, and is deemed to be able to participate until the end of the study
排除标准
- •1) Subjects with only local lymph node metastasis (N1, lymph node metastasis below aortic junction)
- •2) Subjects who have had any of the following prior treatments
- •- If you started ADT 12 weeks before registration
- •- If ARTA (Abiraterone, Enzalutamide) is started 12 weeks before registration
- •- Patients who received cytotoxic anticancer drugs or immunotherapy for other second generation ARTA (such as darolutamide) or prostate cancer prior to registration
- •3) In the case of receiving radiation therapy within two weeks of registration
- •4) If there is an hypersensitivity to the clinical trial drug (Docetaxel)
- •5) In the case of taking azole-based antifungal drugs (myconazole, ketoconazole, itraconalzole, etc.), cyclosporin, terpenadin, erythromycin, clarithromycin, indinavir, nephazodon, nelpinavir, lithonavir, and tetrachyne, boricholivirin, etc
- •6) A drug containing polysorbate 80 has a history of severe hypersensitivity (e.g., carbazetaxel, tosilizumab, etc.)
- •7) A subjects who have medical problem within 6 months before study registratio : stroke, MI, severe/unstable angina pectoris, CHF (NYHA class III or IV)
- •8) If you have been diagnosed with another malignant tumor in the past two years. However, properly treated skin basal cell cancer or squamous epithelial cell cancer, cervical intraepithelial cancer, and thyroid cancer except for stage 4 can participate in the study.
- •9) Unregulated hepatitis B (registered HBV DNA level < 2000 IU/mL for chronic hepatitis B or HBV carrier) or those who have suffered from or are currently infected with hepatitis C (registered if HCV-RNA is negative)
- •10) Human immunodeficiency virus (HIV) infection confirmed
- •11) Medical conditions that may hinder research participation, such as severe active or uncontrolled infections (bacteria, viruses, and fungal infections)
- •12) When a subject of a gynecological clinical trial who is sexually active refuses to use a medically appropriate contraceptive method
- •13) Other serious illnesses or medical conditions
- •14) A subjects who is deemed inappropriate by other researchers
研究者
相似试验
进行中（未招募）
不适用
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck CancerEstudio de fase III randomizado de una quimioterapia de inducción basada en el Docetaxel en pacientes con cáncer de cabeza y cuello localmente avanzado N2/N3 (DeCIDE) - DeCIDEPhase III trial of induction therapy with docetaxel followed by chemoradiotherapy versus chemoradiotherapy alone in patients with nodal stage N2 or N3 head and neck cancerEUCTR2006-002335-24-ESniversity of Chicago400
未知
3 期
Randomized phase III trial of Docetaxel versus docetaxel plus S-1 for second-line treatment of non-small cell lung cancer (NSCLC)JPRN-UMIN000001826The Japan-multinational Trial Organization860
进行中（未招募）
1 期
A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus Zoledronic Acid plus Strontium-89 in Hormone Refractory Prostate Cancer metastatic to bone. - TRAPEZE: phase II/III efficacy and safety clinical trial in Hormone Refractory Prostate CancerHormone refractory Prostate Cancer (HRPC)EUCTR2004-002295-41-GBThe University of Birmingham757
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270